Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases

Chi-Kang Teng1 | Chieh-Lung Chen1 | Ting-Han Chen1 | Wen-Chien Cheng1,2 | Chih-Yen Tu1,2

Abstract
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor pathways for the treatment for EGFR-mutated, metastatic non-small cell lung cancer is supported by previous randomized controlled trials. However, the use of second-generation irreversible EGFR tyrosine kinase inhibitor (TKI) dacomitinib in combination with antiangiogenic therapy has not been reported in the literature. Here, we report the case of a 73-year-old man who presented with hemoptysis and dyspnea on exertion and was diagnosed with right upper lung adenocarcinoma with pleural metastasis and L858R mutation. The second case is of a 60-year-old woman who presented with low back pain and was diagnosed with right lower lung adenocarcinoma with bone metastasis and L858R mutation. Both patients underwent first-line therapy with the TKI dacomitinib in combination with bevacizumab. The first patient showed a nearly complete response, and the second patient showed a partial response after the combination therapy and no severe side effects.

KEYWORDS
angiogenesis inhibitors, bevacizumab, combined modality therapy, dacomitinib, epidermal growth factor receptor

INTRODUCTION
Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor pathways in patients with EGFR-mutated, metastatic non-small cell lung cancer (NSCLC) has previously been reported in randomized controlled trials (RCTs), including RELAY,1 JO25567,2 and NEJ026,3 to increase progression-free survival (PFS). These RCTs were limited to the use of erlotinib, a first-generation EGFR tyrosine kinase inhibitor (TKI), in combination with ramucirumab1 or bevacizumab.2,3 A real-world study reported that the combination of afatinib, a second-generation EGFR TKI, and bevacizumab is an effective therapy.4 However, to the best of our knowledge, no published report has so far discussed the efficacy and safety of dacomitinib, another second-generation irreversible EGFR TKI, in combination with antiangiogenesis therapy. Here, we report two patients with L858R-mutated, metastatic lung adenocarcinoma who gained benefits from receiving dacomitinib and bevacizumab combination therapy and experienced no severe side effects.

CASE REPORT
Case 1
A 73-year-old man visited our hospital complaining of hemoptysis for 1 week accompanied by dyspnea on exertion. Chest radiography and computed tomography (CT) revealed a large mass in the right upper lung (RUL) with a diameter of approximately 10.6 cm (Figures 1a,b), mild right pleural effusion with pleural calcification, and enlarged lymph nodes in the right paratracheal and
hilar regions. Additionally, brain magnetic resonance imaging (MRI) revealed a metastatic lesion in the left frontal lobe (Figure 1c). The patient subsequently underwent bronchoscopic endobronchial ultrasound biopsy and was diagnosed with stage IV lung adenocarcinoma with L858R point mutation in exon 21.

He received first-line therapy with dacomitinib (30 mg, daily) plus bevacizumab (7.5 mg/kg, every 3 weeks). The results of follow-up imaging performed after 3 months showed decreased primary tumor size in chest CT (Figure 1d,e) and improved brain metastasis in brain MRI (Figure 1f). There were also no obvious side effects, except mild skin rash development.

**Case 2**

A 60-year-old woman visited our hospital with a complaint of low back pain for 2 months accompanied by chronic cough. Chest radiography and bone scan demonstrated a mass in the right lower lung (RLL) as well as lung-to-lung and lumbar spine metastases (Figures 2a,b). She was also diagnosed with
stage IVb lung adenocarcinoma with spine metastasis and L858R point mutation in exon 21. Dacomitinib (30 mg daily) plus bevacizumab (7.5 mg/kg, every 3 weeks) was administered as the first-line therapy. Follow-up chest radiography performed after 2 months showed a significantly decreased primary tumor size. There were also no obvious adverse effects, except self-limited mild epistaxis and skin peeling on the feet. After 6 months of undergoing therapy, both patients remained stable with no signs of disease progression.

**DISCUSSION**

Here, we report two cases of metastatic lung adenocarcinoma with driver gene L858R mutation. The patients received first-line therapy with dacomitinib plus bevacizumab and showed an excellent response to it. No obvious severe adverse effects were noted.

Lung cancer, especially NSCLC, is the leading cause of cancer-related death worldwide. The development of EGFR TKIs has markedly improved the treatment of advanced NSCLC. Approximately 80%–90% of patients with EGFR-mutated NSCLC will have either an exon 19 deletion or a common L858R point mutation. Both these mutations are sensitive to EGFR TKIs. However, several studies have previously reported that patients with exon 19 deletions treated with EGFR TKIs had better outcomes compared with those with L858R substitutions.\(^5\)\(^,\)\(^6\) Therefore, NSCLC caused by the two mutations should be treated as distinct types of NSCLC.

Several studies have proved that the combination therapy comprising EGFR TKI and antiangiogenesis therapies has an important role in improving PFS. Both RELAY and NEJ026 disclosed that erlotinib plus antiangiogenesis therapy resulted in longer PFS compared with erlotinib alone as the first-line therapy for EGFR-mutated, metastatic NSCLC.\(^1\)\(^,\)\(^3\) The combination of EGFR TKI and antiangiogenic drugs seems to be more beneficial for patients with L858R mutation compared to those with exon 19 deletion.\(^1\)\(^,\)\(^3\)

Dacomitinib is an irreversible pan-HER TKI that targets the kinase domains of EGFR, ErbB2, and ErbB4 of the EGFR signaling pathway. As an irreversible inhibitor, dacomitinib exerts pharmacodynamic effects for a longer duration compared with first-generation TKIs, which were considered as the alternative first-line therapy for EGFR-mutated NSCLC in the ARCHER 1050 trial.\(^7\) Furthermore, subgroup analysis with exon 21 L858R mutation showed that the median overall survival for patients receiving dacomitinib was 32.5 months, whereas that for those receiving gefitinib was 23.2 months.\(^8\) Nonetheless, compared with gefitinib, dacomitinib has a higher rate of side effects.\(^7\) According to these studies, dacomitinib and antiangiogenesis therapy could provide a survival benefit to patients with L858R mutation, which is worthy of further discussion.

In this study, the patients showed a good response to combination therapy with dacomitinib and bevacizumab with a reduced standard dose without obvious severe side effects, which was comparable with previous studies on the combination of EGFR TKI and antiangiogenesis therapies. The standard dose of dacomitinib is 45 mg per day, whereas bevacizumab should be administered at a dose of 15 mg/kg for 3 weeks, according to previous RCTs.\(^1\)\(^–\)\(^3\)\(^,\)\(^7\) However, both patients in this study received 30-mg/day dacomitinib plus 7.5 mg/kg bevacizumab every 3 weeks, as the first-line therapy. A previous study showed that the 7.5-mg/kg dose was as effective as the 15-mg/kg dose when used in combination with chemotherapy, for the treatment of patients with nonsquamous NSCLC.\(^9\) In a recent real-world study conducted in Taiwan, 57 patients received afatinib and bevacizumab as the initial therapy; of these, 56 patients (98.2%) received a dose of 7.5-mg/kg bevacizumab for each cycle mainly because it is not being covered by the National Health Insurance in Taiwan. A median PFS and an overall survival of 23.9 and 45.9 months, respectively, were observed, suggesting that a reduced bevacizumab dose offered an efficacy similar to that provided by the full dose.\(^4\) Another real-world study
demonstrated that an initial dose of 30-mg dacomitinib also provided disease control benefits. In the current report, the patient in case 1 had a bodyweight of only 33 kg, and both patients received dacomitinib and bevacizumab combination therapy. Therefore, the patients received 30 mg of dacomitinib per day plus the 7.5 mg/kg dose of bevacizumab every 3 weeks as the initial therapy, to prevent the occurrence of severe side effects. During the treatment course, the two patients did not have diarrhea, stomatitis, or fatigue; however, they experienced mild acneiform skin rash, skin peeling, and mild self-limited epistaxis.

Moreover, the novel combination therapy demonstrated clinically meaningful efficacy against brain metastases in the first case. Although the phase 3 ARCHER-1050 study did not assess the efficacy of dacomitinib in patients with brain metastasis, several studies have reported that dacomitinib demonstrates efficacy in improving the central nervous system of patients with EGFR TKI-naïve EGFR-mutated NSCLC in actual clinical settings. The outcome of the first case described in this study support the aforementioned findings. Both patients are currently stable after 6 months of therapy. Although the follow-up time was around half a year, we wanted to report this novel combination therapy as soon as possible, for which no existing reports are available, to the best of our knowledge.

In conclusion, our patients with L858R-mutated, metastatic lung adenocarcinoma showed an excellent response to this novel combination therapy, with no obvious side effects. However, sufficient follow-up is essential to confirm whether this combination therapy resulted in a longer PFS compared with dacomitinib monotherapy. Further RCTs are needed to establish whether dacomitinib plus antiangiogenic drugs can be a standard therapy for EGFR-mutated metastatic NSCLC.

CONFLICT OF INTEREST
The authors declare no conflict of interest.

REFERENCES
1. Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–69.
2. Seto T, Kato T, Nishio M, Goto K, Atagi S, Hosomi Y, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–44.
3. Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–35.
4. Hsu PC, Huang CY, Wang CC, Kuo SC, Chu CH, Tung PH, et al. The combination of afatinib and bevacizumab in untreated EGFR-mutated advanced lung adenocarcinoma: a multicenter observational study. Pharmaceuticals (Basel). 2020;13(11):331.
5. Li WQ, Cui JW. Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments. J Cancer Res Clin Oncol. 2020;146(9):2329–38.
6. Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in egfr-mutated non-small cell lung cancer. J Thorac Oncol. 2017;12(4):612–23.
7. Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–66.
8. Mok TS, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J Clin Oncol. 2018;36(22):2244–50.
9. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227.
10. Zhang J, Wang Y, Liu Z, Wang L, Yao Y, Liu Y, et al. Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. Thorac Cancer. 2021;12(24):3407–15.
11. Peng W, Pu X, Jiang M, Wang J, Li J, Li K, et al. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: a brief report. Lung Cancer. 2021;152:66–70.

How to cite this article: Teng C-K, Chen C-L, Chen T-H, Cheng W-C, Tu C-Y. Bevacizumab plus dacomitinib combination therapy for L858R-mutated metastatic lung adenocarcinoma: A report of two cases. Thorac Cancer. 2022;13:1427–30. https://doi.org/10.1111/1759-7714.14396